|
| | Cinobufotalin Basic information |
| Product Name: | Cinobufotalin | | Synonyms: | cinobufotalin venom toad;Cinobufotalin std.;5BETA,20[22]-BUFADIENOLIDE-14,15BETA-EPOXY-3BETA,5ALPHA,16BETA-TRIOL 16-ACETATE;14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-22-dienolid16-5-beta-bufa-2;CINOBUFOTALIN(RG);14,15b-Epoxy-3b,5a,16b-trihydroxy-5b,20(22)-bufadienolide 16-acetate;5β,20(22)-Bufadienolide-14,15β-epoxy-3β,5α,16β-triol 16-acetate, 14,15β-Epoxy-3β,5α,16β-trihydroxy-5β,20(22)-bufadienolide 16-acetate;14,15-Epoxy-14H-cyclopenta[a]phenanthrene, bufa-20,22-dienolide deriv. | | CAS: | 1108-68-5 | | MF: | C26H34O7 | | MW: | 458.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1108-68-5.mol |  |
| | Cinobufotalin Chemical Properties |
| Melting point | 259-262° | | alpha | D20 +11° | | Boiling point | 627.3±55.0 °C(Predicted) | | density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMF: 10 mg/ml; DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml; DMSO: 5 mg/ml; Ethanol: 5 mg/ml | | form | White to off-white solid. | | pka | 14.67±0.70(Predicted) | | CAS DataBase Reference | 1108-68-5 |
| Hazard Codes | T+ | | Risk Statements | 26/27/28 | | Safety Statements | 22-36/37/39-45 | | RIDADR | UN 2811 6.1/PG 1 | | WGK Germany | 3 | | RTECS | EI2991000 | | HazardClass | 6.1(a) | | PackingGroup | II | | Toxicity | cat,LD50,intravenous,200ug/kg (0.2mg/kg),"Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963Vol. -, Pg. 189, 1963. |
| | Cinobufotalin Usage And Synthesis |
| Description | Cinobufacin is an indole-type total alkaloid extracted from the dried toad skin of Chinese toad, which has the functions of clearing away heat and detoxifying, reducing swelling and pain, promoting blood circulation and removing blood stasis, softening and dispelling knots. | | Application | Cinobufacin can be used for a variety of middle and advanced tumors (lung cancer, breast cancer, cervical cancer, digestive system tumors such as primary liver cancer, gastric cancer, colon cancer, etc.), chronic hepatitis B, especially for chronic hepatitis B virus carriers. Especially prominent. | | Side effects | For individual patients, if the dosage is too large or the interval between two administrations is less than 6 to 8 hours, chills and fever may occur about 30 minutes after administration; a small number of patients have local irritation or phlebitis after long-term intravenous infusion, which will slow down the infusion rate. Very few patients may also appear urticaria, dermatitis and so on. |
| | Cinobufotalin Preparation Products And Raw materials |
|
